Építés alatt – nem éles oldal
Belépés
Toborzás még nem indultFázis nélkül

Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

A legfontosabb adatok

Ki végzi
Nanjing Miracle Biotechnology Co., Ltd.
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
24 fő, tervezett
Kezdés
2026. szept.
Várható befejezés
2027. dec.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • CHT105
A regiszteradat frissítve
2026. szeptember 10.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with immune thrombocytopenia (ITP, a low platelet count caused by the immune system) that came back or did not respond to treatment. They will receive CHT105, a donor CAR-T cell therapy.

Életkor
18 to 65 years
Nem
All sexes
A betegség stádiuma
Relapsed or refractory ITP by the 2009 IWG criteria. Platelet count below 50×10⁹/L on at least two tests in a row. No other cause of low platelets.
Korábbi kezelés
At least one earlier ITP treatment, such as glucocorticoids, immunoglobulins, azathioprine, danazol, cyclophosphamide or rituximab. No disease-modifying immunosuppressive agents within five half-lives, and no biological agents within 4 weeks, before joining.
Biomarker vagy leletérték
CD19/CD70 must be found on blood B-cells by flow cytometry. Also either a past response to one ITP treatment (platelets >50×10⁹/L) within 3 years, or a bone marrow test that fits ITP.

A részvétel fő kizáró okai

  • Active or suspected infection that is not controlled
  • Hepatitis B, hepatitis C, HIV or syphilis infection
  • Cancer within the past 5 years
  • End-stage kidney failure or poor heart function
  • Pregnant, breastfeeding or planning pregnancy

A regiszter feltételei, szó szerint

Mind a 15 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥18 and ≤65 years (inclusive), no restriction on gender
  • Positive expression of CD19/CD70 on peripheral blood B-cells as determined by flow cytometry
  • Key organ functions shall meet the following requirements:; 1). Bone marrow function: a. Absolute neutrophil count ≥1×10⁹/L (no colony-stimulating factor therapy within 2 weeks prior to testing, except for neutropenia caused by underlying disease); b. Hemoglobin ≥60 g/L; 2). Liver function: ALT ≤3×ULN (except for ALT elevation due to underlying disease); AST ≤3×ULN (except for AST elevation due to underlying disease); TBIL ≤1.5×ULN (except for TBIL elevation due to underlying disease); 3). Renal function: Creatinine clearance (CrCl) ≥30 mL/min (calculated by the Cockcroft-Gault formula, except for decreased CrCl caused by underlying disease); 4). Coagulation function: International Normalized Ratio (INR) ≤1.5×ULN; Prothrombin Time (PT) ≤1.5×ULN; 5). Cardiac function: Good hemodynamic stability; 4.Female subjects of child-bearing potential and male subjects with partners of child-bearing potential must use medically-accepted contraceptive measures or practice abstinence during study treatment and for at least 6 months after the end of study treatment. Female subjects of child-bearing potential must have a negative serum HCG test result within 7 days prior to study enrollment and shall not be lactating; 5.Voluntarily participate in this clinical study, provide signed informed consent, have good compliance, and be willing to comply with follow-up procedures; 6.Diagnosed with relapsed/refractory immune thrombocytopenia (ITP) according to the 2009 International Working Group (IWG) consensus criteria; 7.latelet count <50×10⁹/L on at least two consecutive occasions. In addition, peripheral blood smear findings shall support the diagnosis of ITP, with no evidence indicating alternative causes of thrombocytopenia (e.g., pseudothrombocytopenia, myelofibrosis). Physical examination findings shall reveal no diseases other than ITP that may cause thrombocytopenia; 8.Subjects shall have received one or more prior therapies for ITP (including but not limited to glucocorticoids, immunoglobulins, azathioprine, danazol, cyclophosphamide and/or rituximab); 9.Subjects must have either a response to one prior ITP therapy (platelet count >50×10⁹/L) within the past 3 years, or bone marrow findings consistent with ITP, to rule out myelodysplastic syndrome (MDS) or other alternative causes of thrombocytopenia; 10.Subjects shall have Prothrombin Time (PT) not exceeding ±3 seconds relative to the normal reference range (or the International Normalized Ratio [INR] within 80%-120% of the normal range); activated partial thromboplastin time (aPTT) not exceeding ±10 seconds relative to the normal reference range; and no history of hypercoagulable state

Ki nem vehet részt

  • Participation in another clinical trial within 3 months prior to enrollment
  • Use of disease-modifying immunosuppressive agents within five half-lives prior to enrollment, or use of biological agents (including but not limited to mycophenolate mofetil, methotrexate, leflunomide, belimumab, etc.) within 4 weeks prior to enrollment
  • Subjects with a severe history of drug allergy or allergic diathesis
  • Presence or suspicion of uncontrolled or treatable fungal, bacterial, viral or other infections
  • Subjects with intolerable cardiac function
  • History of malignant neoplasm within the past 5 years
  • Subjects with end-stage renal failure
  • Subjects positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer above the upper limit of detection; subjects positive for hepatitis C virus (HCV) antibody with detectable peripheral blood HCV RNA; subjects positive for human immunodeficiency virus (HIV) antibody; subjects with positive syphilis test
  • Presence of psychiatric disorders and severe cognitive impairment
  • Subjects with congenital immunoglobulin deficiency
  • Female subjects who are pregnant or planning to become pregnant
  • Subjects whom the investigator considers ineligible for enrollment for any other reason

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Primary Objective: To evaluate the safety and efficacy of CHT105 Injection in subjects with relapsed/refractory autoimmune diseases.

A teljes eredeti leírásKevesebb

Secondary Objective:To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of CHT105 Injection.

Indication: Immune Thrombocytopenia (ITP)

A vizsgálat csoportja

  • Treatment groupA vizsgált kezelés

    Kezelés: CHT105

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Cell Injection Targeting CD19/CD70 (CHT105) in Patients With Relapsed/Refractory Autoimmune Diseases
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07811622: ki vehet részt
A regiszteradat frissítve
2026. szeptember 10.